(E)-methyl 4-(4-(3-(1H-indol-3-yl)acryloyl)phenoxy)butanoate | 1615690-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (E)-methyl 4-(4-(3-(1H-indol-3-yl)acryloyl)phenoxy)butanoate
• 英文别名: methyl 4-[4-[(E)-3-(1H-indol-3-yl)prop-2-enoyl]phenoxy]butanoate
• CAS: 1615690-92-0
• 化学式: C₂₂H₂₁NO₄
• 分子量: 363.413
• InChiKey: WYCPYCWVQCHFIJ-JLHYYAGUSA-N

物化性质

• 熔点：
  135-137 °C
• 沸点：
  593.823±50.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  1.229±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  68.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对羟基苯乙酮 在 哌啶 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 28.0h， 生成 (E)-methyl 4-(4-(3-(1H-indol-3-yl)acryloyl)phenoxy)butanoate
  参考文献：
  名称：

  Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents

  摘要：

  A series of novel indole-chalcone fibrates were synthesized and their hypolipidemic activity was evaluated in triton WR-1339 induced hyperlipidemic rat model. Preliminary studies indicated that the hybrids 19, 24 and 29 exhibited potent in vitro antioxidant and significant in vivo antidyslipidemic effects. Our results suggest that these new hybrid architectures may serve as promising leads for the development of next generation lipid lowering agents. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.04.085

文献信息

• Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents
  作者：Koneni V. Sashidhara、Ranga Prasad Dodda、Ravi Sonkar、Gopala Reddy Palnati、Gitika Bhatia

  DOI：10.1016/j.ejmech.2014.04.085

  日期：2014.6

  A series of novel indole-chalcone fibrates were synthesized and their hypolipidemic activity was evaluated in triton WR-1339 induced hyperlipidemic rat model. Preliminary studies indicated that the hybrids 19, 24 and 29 exhibited potent in vitro antioxidant and significant in vivo antidyslipidemic effects. Our results suggest that these new hybrid architectures may serve as promising leads for the development of next generation lipid lowering agents. (C) 2014 Elsevier Masson SAS. All rights reserved.